Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Oncopeptides AB to Present Data from OCEAN Study at International Myeloma Workshop (IMW) Transcript

Sep 12, 2021 / 02:00PM GMT
Martin Duvall

Good afternoon, and good morning, everyone. I'm Marty Duvall, CEO of Oncopeptides. And welcome to the Oncopeptides' post IMW Webcast.

Yesterday at the IMW meeting here in Vienna, Dr. Fredrik Schjesvold presented a late-breaking abstract on the OCEAN data set, representing the first introduction of trial details in a peer-reviewed public setting. Over the past 24 hours, we have been pleased to hear the feedback on this excellent presentation, as well as the strong interest in the OCEAN data results.

Today, you will have the opportunity to hear directly from Dr. Fredrik Schjesvold and participate in a Q&A on the data and perspectives. And to present your question, there's a form in the webcast where you can type it in, and we'll have the opportunity to talk about it.

If you could flip the slide forward. Importantly, we will be making some forward-looking statements today. So, please refer to all of our submissions for appropriate balance on representations and warranties of the data as we describe it.

Next slide, please. So, the format today will be that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot